FY2023 Report of Activities
I. Report of Major Activities
Epidemiologic data on mortality and cancer incidence from the A-bomb survivors (the Life
Span Study [LSS], In utero study, Adult Health Study [AHS]) and their children (the F1generation studies) have long been a primary basis for national and international estimatesof the risks of cancer and other diseases from exposure to ionizing radiation. The unique
importance of the LSS study stems from the combination of its large size, wide range of
exposure levels, inclusion of all ages at exposure, and long-standing, high-quality follow-up
of mortality and cancer incidence. The periodic follow-up and report of cohort data is only
one facet of RERF’s research activities. Clinical examinations and longitudinal serial
collection of biosamples provide more detailed information on health conditions of interest,
including the pathogenesis of conditions in relation to radiation exposure. RERF’s
Department of Molecular Biosciences collaborates with the Departments of Clinical Studies,
Epidemiology, and Statistics, to further address the nature and extent of genetic andepigenetic effects associated with health risks. The opportunity to integrate these highquality, long-standing epidemiologic, dose, and clinical data with serial collections ofbiospecimens over time is unique to RERF and demands that the best possible science be
conducted for the benefit of survivors and their children, the radiation research community,and global radiation protection.
RERF’s strategic plan focuses on continued excellence, using cutting edge methods toanswer key questions in radiation science, emphasizing collaboration and communication.
As we move forward, RERF will place a high priority on integrated research programs,
leveraging expertise through collaboration with Japanese and international institutions.
1. Research Projects Examining A-bomb Survivors Health1) Radiation and Cancer:
 [Life Span Study (LSS)/In-utero/ F1 Update (RP 1-75 Sakata, RP 2-61 Sugiyama, RP 4-75
Sakata)]: The Dept. of Epidemiology maintains three major cohort studies for: 1) atomic
bomb survivors (LSS), 2) in utero survivors, and 3) offspring of survivors (F1). Around 22%
of LSS cohort members were still alive at the end of 2019, including 69% of those who wereless than 10 years old at the time of bombing. Moreover, 74% of the in utero and 87% of theF1 cohorts were still alive as of 2019. These cohorts are the basis of RERF’s major analysesof radiation-related risk in humans. Individual radiation doses have been estimated andcontinuously revised as newer techniques become available. In the past year, we showed thatthe solid cancer mortality dose-response in A-bomb survivors exhibited a borderline
significant upward curvature among males and significant upward curvature among females(Brenner AV et al., Radiat Res, 2022); that atomic bomb radiation exposure did not
substantially affect survival after first solid cancer diagnosis in A-bomb survivors (Sposto R
et al. Cancer Epidemiol, 2023), and that radiation increased the risk of prostate cancer, evenafter accounting for effect of prostate-specific antigen (PSA) screening tests (Utada M et al,
Radiat Res, 2023). Analysis of the F1 cohort study is ongoing, with the first stage analysis
to be completed in 2024, pending update of the exposure information for calculation of
DS02R1 dose for a remaining subset of F1 subjects.
 [Radiation and Hematological Malignancies: Myelodysplastic Syndrome (MDS), RP 1-17,
Imaizumi] Atomic bomb survivors have a higher risk of hematological malignancies even1

50 years post radiation exposure. Recent genome analyses showed that blood samples
contain several gene mutations that might be observable before clinical diagnosis. Using
next-generation genome analysis technology, we are searching for mutations in seriallystored blood samples of AHS participants who developed MDS to uncover the mutational
process of expanding and diminishing clones observed before diagnosis of MDS. In an
analysis of whole genome single nucleotide variants, we identified distinct mutationalsignatures between expanding and diminishing clones, indicating different mutational
process in the development of these two distinct clone types.
 [Radiation and Hematological Malignancies: Leukemia, RP-P1-23, Yoshida N] A-bomb
survivors had a high risk of hematological malignancies shortly after exposure. Little is
known about the genomic alterations in these leukemia cases, but the alterations could play
critical roles in radiation-induced leukemogenesis. To reveal the genomic landscape of theleukemia cases, we started a pilot study of targeted-sequencing analysis using DNA andRNA extracted from a small number of stored AHS formalin-fixed paraffin embedded(FFPE) samples. If the pilot study is successful, we will launch a full-scale study.
 [AHS Genome Wide Association Study, RP-P2-22, Hayashi T]: Genome-wide association
studies (GWAS) on A-bomb survivors can lead to a better understanding of individual
radiation-related risk of carcinogenesis risk and other health outcomes. In preparation forthe planned AHS-GWAS, feasibility studies to evaluate genomic DNA extraction andgenotyping were conducted using old blood smears and chromosome preparations obtained
from A-bomb survivors. While DNA was successfully extracted from recent smear samples,the quality of the extracted DNA was much lower for samples older than 10 years. However,use of the REPL-g multi-combination system led to improved results, resulting in acceptable
power even in a single nucleotide polymorphism (SNP) array testing conducted with
720,000 probes. Further testing will be conducted of older samples, and if results are
acceptable, a full-scale study will be launched.

2) Radiation and Non-Cancer Effects:
 [Adult Health Study (AHS) updates RP 2-75, Ohishi]: In the past year, we found thatradiation dose is potentially associated with risk of diabetes, especially amongst those
exposed at younger ages in atomic bomb survivors, 1969-2015 (Tatsukawa et al., J Clin
Endocrinol Metab, 2022), and that there was a suggestion of excess risk of multiple myeloma
for definite/probable cases with an ERR/Gy = 0.43; 95% CI, <–0.01 to 2.1 (Yoshida N.
Blood Adv, 2023). There was no clear effect of radiation dose on late-life neurocognitive
function in atomic bomb survivors exposed as children (Ishihara K et al., Radiat Res, 2022),
and no significant effect of radiation was observed on scores of metacognition, emotional
regulation, motivation/organization, and processing speed on survivors exposed in utero(Kitamura H et al., Radiat Res, 2023).
 [Cataract Study RP 5-15, Hida]: Previous ophthalmological studies at RERF used nonstandardized cataract evaluation methods, resulting in potential misclassification ofoutcomes. We completed a primary re-analysis of cataract prevalence using data frommodern assessments of cataracts in AHS subjects. The reanalysis used generalized
estimating equations (GEE) to account for cataract outcome in both eyes, and incorporated
information on informative censoring due to individuals who had undergone eye surgery andcould not be evaluated for cataracts. Preliminary results indicate an increased risk of2

posterior subcapsular cataracts (PSC) with radiation dose. No significant dose-related
associations were observed for cortical opacities or nuclear cataracts (RP 5-15).
 [Radiation and Atherosclerosis, RPs 2-11 and 1-23-2, Nakamizo]: Associations between
radiation and atherosclerosis or circulating inflammatory markers have been observed in Abomb survivors. To evaluate the potential mechanisms of radiation-induced atherosclerosis,
we are focusing on possible mediation by 1) clonal hematopoiesis / T-cell aging /inflammation and 2) abnormal vascular repair. Quality assessment of cytokine
measurements was completed, and a manuscript was submitted to an international journal.
Statistical analysis of AHS data has been initiated.
 [Radiation and Clonal Hematopoiesis (CH), RP 1-23-1 and RP 1-23-3, Yoshida K &Kusunoki Y]: MBS Department’s clonal hematopoiesis (CH) study was initiated using stored
blood samples obtained from AHS participants to examine the occurrence of CH in thesurvivors and its possible relevance to various diseases. We have already obtained informed
consent (IC) and are analyzing data of somatic mutations detected by whole exome
sequencing (WES). A further study using stored blood samples collected over time isplanned to clarify the dynamics of hematopoietic cell proliferation and expansion during theprocess of health recovery after the atomic bombing (RP 1-23-1). Methods to characterize
and track clonal hematopoiesis following radiation exposure have been established incollaboration with outside universities (RP 1-23-3).
[RP 1-23-1, Yoshida K]: A related clonal hematopoiesis program to clarify the relationships
between clonal hematopoiesis and the healing process, as well as the relationship between
clonal hematopoiesis and inflammatory diseases during that process, is underway in concert
with Nagasaki University, Kyoto University, and the University of Tokyo. Preliminary work
using stored pathological tissues to search for biomarkers of radiation exposure has begun
in collaboration with the private-sector Shimadzu Corporation and Kyoto University.
2.

Research Projects on the Health of A-bomb Survivors Children (F1) [Trio Study of Hereditary Effects, RP 3-23, Uchimura A]: Elucidating the potential
hereditary genetic effects of A-bomb radiation has been a key question since theestablishment of RERF, and we have long planned to analyze the whole genome of exposedparents and children to answer this question. In 2023, the research protocol was approvedby the Executive Committee; a meeting was held with the study’s External Advisory
Committee, and suggestions from the committee were incorporated into a revised RP.
Following a briefing session with the media and IRB approval, we started to obtain reconsent for participating trios and initiated a pilot study of a small number of families toestablish a pipeline for whole-genome sequencing (WGS) and analysis in collaboration withNCI and RIKEN. Analyses will be performed using a secure external cloud server (RP 323).
 [Platform Protocol: F1 Offspring Clinical Study (FOCS), RP 4-10, Ohishi] Heritable effects
of exposure to ionizing radiation are a public health concern, but very little human data exist
on the potential risk of common adult-onset multifactorial diseases (hypertension,
hypercholesterolaemia, diabetes mellitus, angina pectoris, myocardial infarction or stroke)in the offspring of exposed persons. Initial examination of the FOCS from 2002 to 2006
provided no evidence for an increased prevalence of adult-onset multifactorial diseases due
to parental radiation exposure. However, incidence data will have less potential for bias than3

prevalence data, indicating the need for a high-quality clinical study continued until thesubjects become elderly, when many multifactorial diseases develop. The analysis plan of
the longitudinal study data (2002–2020) has been developed within the interdepartmental
FOCS Analysis Working Group. Data have been thoroughly checked, and we havecompleted the first stage of the multi-state modelling longitudinal analysis to investigate theassociation between parental A-bomb radiation dose and occurrence of multifactorial diseasein the study cohort. The first stage of analysis included modelling of transitions between
healthy, ill, death, and lost-to-follow-up states (RP 4-10).
3. Research to Elucidate Individual Doses and Effects from the A-bomb
 Radiation Dosimetry [RP 18-59, PI: Sposto]: Department of Statistics members havecontinued work with the international Organ Dosimetry Working Group (ODWG) which isdeveloping revised organ doses for RERF’s epidemiological studies based on modern,sophisticated J45 computational phantoms. We have almost completed revision and quality
control of the software necessary for the computations and are awaiting completion of theextensive simulations by means of which the necessary response functions for new organ
dosimetry will be determined.
A simulation study based on 20 generalized survivor scenarios reported that the updated
phantom series is expected to provide dose improvements to several important organs,including active marrow, colon, and stomach wall (15-20% impact on total dose). The new
dosimetry system is expected to particularly improve neutron dose estimates (up to 2-folddifference) and organs unavailable in the previous phantom series (Griffen et al Rad Envi
Biophys 2022).
As a further investigation of the issue of RBE, recently studied in the context of all solidcancer incidence by Cordova, Cullings, et al., we are collaborating with Dr. Sato at JAEA
and Dr. Kai at Nippon Bunri University to utilize the J45 computational phantoms inconjunction with PHITS simulation software, currently used to compute the new organ
dosimetry, to assess theoretically the RBE of neutrons in each organ for representativeshielding categories for typical Life Span Study (LSS) subjects. A manuscript is currently indevelopment.
Using biodosimetry data, we showed a strong relationship between stable chromosome
aberration rate measured by fluorescent in situ hybridization (FISH) and the DS02R1
radiation dose estimates in 1,868 atomic bomb survivors. However, persistent differencesof the dose-response relationship by shielding category suggests that further improvement isneeded in the physical dosimetry (Sposto et al. Rad Res, 2023).


Spatial analysis [No RP, PI: Yamamura]: Geographical variation in incidence and mortality
rates might remain even after controlling for known background, shielding, and effectmodifying variables. Controlling for these effects could improve radiation risk estimates in
A-bomb survivors. In collaboration with investigators at Hiroshima University, we aredeveloping methods for spatio-temporal analysis of rates from count data using generalized
fused-Lasso Poisson models (Yamamura, Ohishi, and Yanagihara 2023, Yamamura, Ohishi,
and Yanagihara 2023).

44. Projects to Release Research Results and to Collaborate with Other Scientific
Organizations
Crucial to the mission of RERF is the dissemination of results of our studies to survivors
and their children, and to the international community. Toward that end we interact withlocal liaison councils representing the communities of Hiroshima and Nagasaki and provide
information via public lectures and other activities. These will be described later in anothersection of this report. With respect to the international community there are several activities
including seminars, workshops, participation at international scientific conferences, andinternational publication of results. In FY2023 RERF hosted six seminars presented bynational and international visitors, and published more than 60 scientific papers.
Collaborative Research Projects
 Ongoing international collaborative research projects
In addition to the above activities the development of national and international
collaborations is essential to help disseminate results and to enhance RERF research
programs. A list of current collaborations is provided below:
a.
b.
c.
d.
e.

Partnerships with the Universities of Hiroshima, Nagasaki, Tokyo, Kyoto, Kurume
Collaboration with the U.S. National Cancer InstituteCollaboration with the University of Florida
Collaboration with the University of Washington
Collaboration with Outside Investigators:
47 Japanese Institutions
9 North American Institutions
10 European Institutions
1 Asian Institution

5. Training Programs for Domestic and Overseas Specialists
1) RERF held a hybrid online and face-to-face epidemiological training course for radiation
biologists. RERF aimed to deepen their understanding of the foundation’s epidemiologicalresearch and to promote interaction among investigators working in radiation research
institutes (August 21–22, 2023; 82 participants consisting of 40 and 42 from inside andoutside RERF, respectively).
2) Due to the effects of COVID-19, the International Council for Health Care of Radiationexposed (HICARE) provided training online. However, the Nagasaki Association for
Hibakushas’ Medical Care (NASHIM) delivered training lectures face-to-face.
Two persons were dispatched as lecturers to the IAEA (International Atomic Energy
Agency)/HICARE International Training Course on Medical Responses to Radiation
Accidents and Disasters held on January 15-18, 2024.
3) There was no invitation for the MHLW-sponsored International Exchange and Research
Program in FY2023 either, so RERF did not recruit trainees from abroad.
4) The Department of Statistics used RERF’s official website to recruit investigators toparticipate in the International Fellowships for Research in Japan program sponsored by
the Japan Society for the Promotion of Science (JSPS). As a result, the department madeone fellowship application.

56. Public Information Programsi)

RERF Open House event
The Hiroshima and Nagasaki RERF laboratories held their 28th and 26th Open House
events, respectively. Although the new coronavirus was downgraded to category 5 under
the infectious disease law in May 2023, RERF continued to consider the impact of thedisease. It held the events on a hybrid basis, combining face-to-face events with limited
numbers of participants and website events. Specifically, the 2023 Open House was heldwith a focus on an exclusive online portal site featuring new content such as a VR
introduction of the examination area (12,609 views). There also were videos posted, five
live-streamed events (about 300 participants in total), and limited in-person activities (about
50 participants out of 260 applications).

ii) Public outreach related to genome sequencing analysis study
RERF has to obtain understanding from the A-bomb survivors, their children, and the local
communities to initiate this study. RERF is preparing for public lectures (symposiums)
focusing on this study to be held in Hiroshima and Nagasaki in April 2024. As part of its
efforts, a guidance session for the mass media was held in Hiroshima and Nagasaki(October 2023, 24 participants). Aside from this, RERF is preparing for an explanatory
session targeting only study participants.
iii) Promotion of public relations activities targeting media
RERF strove to respond to media requests for information in an effort to ensure that its
coverage was fair and unbiased. As part of PR activities for the genome sequencing analysis
study, RERF held a guidance session for the media this year. This helped the foundation
maintain contact with the media efficiently. In addition to this, RERF reported on the firstmeeting of the External Advisory Committee on Biosample Usage (6/1), the 13th regularmeeting of the Board of Councilors (6/22), and the introduction of the new Directors (6/23).
It also held a press conference, sent out a press release, and fielded media requests for thesecond meeting of the External Advisory Committee on Biosample Usage (8/23). The
number of published articles featuring RERF in FY2023 totaled 103 as of March 31, 2024.
iv) Enhancement of social media-related activities
RERF has opened social media accounts, including Facebook and X (formerly Twitter).
Using social media requires thorough risk management, and RERF is advancing its
measures to consistently develop follower support for the foundation and not merely
increase follower numbers. As of March 31, 2024, RERF had 889 followers on its Facebook
page and 707 followers on its English and Japanese accounts on X (formerly Twitter).
v) Vitalization of video-production system
RERF is preparing to produce video content to obtain the understandings of the A-bomb
survivors, their children, and local communities for its planned genome sequencing analysis
study. RERF is also preparing for video production, including interviews with scientists
about the specific research projects in which they are engaged, as well as other related
stories, as an enhancement of synopses introducing RERF research papers.

6vi) Enhancement of the RERF website
•

•
•



For the FY2023 Open House, RERF effectively attracted viewers to its official website
by utilizing targeted banners and Facebook advertising for the first time. Owing tothese successful approaches, the bounce rate (the percentage of visitors that leave a
webpage without moving to pages other than the top page) of the Open House website
considerably improved from 86.55% in FY2022 to 71.55% in FY2023.
Starting in FY2018, new easy-to-follow synopses of published papers have beenposted on the public website (six synopses posted in FY2023).
RERF continued its website’s regular updates. In FY2023, 16 articles were added to
the What’s New section, and 41 posts of bid-related information were made. RERF
also updated the pages of executive and research staff according to structural changes
and posted the report of the previous year’s activities and other materials on workand finance.
As of March 31, 2024, the event counts (views) of the RERF website were 1,080,000,
with the daily average being about 2,958, and the website visitors totaled 170,000, withthe daily average being about 466.

vii) Facility tour program
Considering the continued concerns about the new coronavirus, RERF held facility tours
but limited the dates to May 26 and August 6 in the first half of the fiscal year. There werea total of 23 participants. As requested by the City of Hiroshima, RERF also held a tour fora group of 20 ambassadors to Japan who had attended the peace memorial ceremony. RERF
also cooperated with the activity being carried out by Hirosaki University Institute ofRadiation Emergency Medicine as part of a human-resource training program run by the
Secretariat of the Nuclear Regulation Authority. It accepted five students and graduate
students learning risk analysis and others and shared the foundation’s history and researchfindings with them. On this tour, the Department of Molecular Biosciences also joined andoffered a tour of laboratories that were not made open to the public on a normal facility
tour. In FY2023, there were thirteen facility tours (about 122 visitors) as of March 31, 2024.
viii) Other PR activities
•
•
•

•

•

Press releases were sent out regarding two studies of high-impact factors. RERF
accepted a media request for an interview, but it did not appear as an article.
The RERF School Visit Program was held—which is an attempt to teach radiation
health effects to school children using readily understandable language. As of March
31, 2024, there were nine school visits (about 480 participants).
The online version of the RERF School Visit Program was held (two visits, 570
participants). By holding the program online, RERF could resolve problems such as
the conflict of schedule between RERF and schools and the unavailability of a venue
due to an excessive number of participants.
RERF held a guidance session with peace volunteer guides and volunteer memory
keepers of A-bomb experiences from external organizations of the Hiroshima Peace
Memorial Museum (nine participants). Since some participants had expressed concern
about their knowledge of radiation in their guiding activities, RERF solicited theresearch staff’s support and provided the participants with a session more detailed thana normal school visit, which was received favorably. A similar guidance session isscheduled for May 2024.
As requested by the Department of Clinical Studies, RERF held a tour of Hijiyama

7Hall for some AHS and FOCS participants. The foundation introduced the building as
an architectural heritage to the participants and provided them with explanations of thesignificance of RERF’s research findings (three total number of days and 36
total participants).

8

（Attachment 1）

FY2023 RERF International Collaborative Activities
I. Participation in international collaborative
activities by RERF directors and staff
members

WHO-related activity
UNSCEAR-related activity
ICRP-related activity
IAEA-related activity

II. Acceptance of visitors from overseas forbriefing and training

3 people (Hiroshima)
2 people Visitors related to HICARE
3 people Visitors related to RERF
(International Exchange
Research Program)
None Visitors related to MEXT

Medical checkup for A-bomb
survivors residing in South
Korea-related activity

1 person

NASHIM-related activity

1 person

Others15 people
Total: 25 people

9 people
None
None

Visitors related to JICA

(Nagasaki)
Visitors related to NASHIM

None

24 people

Total: 33 people(Hiroshima: 9 people, Nagasaki: 24 people)

I. Participation in international collaborative activities by RERF directors and staff
members (excluding participation in international scientific meetings)
In italics: Funding Organization

1. World Health Organization (WHO)-related activity (3 people)
RERF (hereinafter, all titles represent those at time of participation)
Kenji Kamiya, Chair, Kazunori Kodama, Executive Director, and Misa Imaizumi, Assistant
Department Chief of Clinical Studies (Nagasaki), attended the 17th Radiation Emergency
Medical Preparedness and Assistance Network (WHO REMPAN) (September 13-15, 2023,
Korea).
2. United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR)-related collaborative activity (2 people)
1) National Institute of Radiological Sciences
Ritsu Sakata, Acting Department Chief of Epidemiology, attended the UNSCEAR domestic
committee meetings (September 26, 2023, Online, and March 6, 2024, Online).
2) RERF
Alina Brenner, Senior Scientist, Department of Epidemiology, attended meetings as a lead
writer for UNSCEAR Epidemiological studies of Radiation and Cancer (June 19, July 10,
August 22, September 13-15, October 30, and December 8, 2023, Online, February 6, andMarch 6, 2024, Online).
3. ICRP (International Commission on Radiological Protection)-related activity (3 people)(1) Alina Brenner, Senior Scientist, Department of Epidemiology, attended meetings as amember of the ICRP Task Group 122 (Update of Detriment Calculation for Cancer)

9(April 13 and October 3, 2023, Online, February 29, 2024, Online).
(2) Preetha Rajaraman, Vice Chair, attended the 7th International Symposium on the
System of Radiological Protection and Committee Meetings at ICRP 2023 asCommittee Member and a Member of the ICRP Task Group 111 (Factors Governing
the Individual Response of Humans to Ionizing Radiation). (November 5-12, 2023,
Tokyo).
(3) Tomoki Nakamizo, Division Chief of Radiology of the Department of Clinical Studies,
Nagasaki, attended meetings as a member of the ICRP Task Group 119 (Radiation
Effects on Diseases of the Circulatory System) (April 25 and June 9, 2023, Online,
January 15, 2024, Online).
4. IAEA (International Atomic Energy Agency)-related activity (0 person)
This activity was not done in FY2023.
5. Medical checkup for A-bomb survivors residing in South Korea-related activity(1 person)
Nagasaki Prefecture
Ayumi Hida, Department Chief, Department of Clinical Studies, Nagasaki, participated in
33rd A-bomb survivors medical checkup in Korea (July 9-13, 2023, Seoul, Korea).
6. Nagasaki Association for Hibakusha Medical and International Cooperation (NASHIM)
related (1 person)
Nagasaki Prefecture
Dr. Imaizumi, Assistant Department Chief of Clinical Studies, Nagasaki, participated in theexchange of opinions on the NASHIM expert dispatch project (September 11-12, 2023,
Korea)
7. Others (15 people)(1) Alina Brenner, Senior Scientist, Department of Epidemiology, gave an invited presentation at the
ISORED meeting (May 16, 2023, Sitges, Spain)(2) Kenji Kamiya, RERF Chair, attended the reception of the 20th anniversary of the Hiroshima
Office of the United Nations Institute for Training and Research (June 30, 2023, Hiroshima).
(3) Osamu Tanabe, Chief Scientist, attended the 17th International Congress for Radiation
Research (August 27-30, 2023, Montreal, Canada)(4) Richard Sposto, Department Chief, Department of Statistics, gave a lecture at the 2023
United Nations Disarmament Fellowship Program (October 2, 2023, Hiroshima)(5) Kenji Kamiya, RERF Chair, gave a lecturer at HICARE’s seminar on the medical care for
A-bomb survivors in Hawaii, USA (October 11-12, 2023, Hawaii, USA).
(6) Hiromi Sugiyama, Assistant Department Chief, Department of Epidemiology, attended aboard meeting of International Association of Cancer Registries (IACR) (October 14, 2023,
Online, November 13, Spain, 2023, February 6, and March 7, 2024, Online).
(7) Hiromi Sugiyama, Assistant Department Chief, Department of Epidemiology, attended Asia
Cohort Consortium (ACC) (October 25-26, 2023, Nagoya).
(8) Ritsu Sakata, Acting Department Chief and Alina Brenner, Senior Scientist, Department of
Epidemiology, gave an invited presentation at the 7th International Symposium On The
System of Radiological Protection ICRP 2023 (November 9, 2023, Tokyo)

10(9) Ayumi Hida, Department Chief, Department of Clinical Studies, Nagasaki, made a presented
at the Satellite Session (Cataracts) of the 7th ICRP International Symposium (November 11,
2023, Tokyo)(10) Kenji Kamiya, RERF Chair, attended as a chair and Richard Sposto, Department Chief,
Department of Statistics, gave a lecture at the 25th International Charles Heidelberger
Symposium on Cancer Research. (November 16-17, 2023, Hiroshima).
(11) Kenji Kamiya, RERF Chair, and Kazunori Kodama, Executive Director, gave a lecture at the
IAEA-HICARE International Training Course on Medical Responses to Radiation Accidents
and Disasters (January 18, 2024, Hiroshima).
(12) Kenji Kamiya, RERF Chair, attended the 2024 Fukushima Medical University International
Symposium on the Fukushima Health Management Survey (March 2, 2024, Fukushima).
II. Acceptance of visitors from overseas for briefing and training (33 people)【Hiroshima 9 people (Online training)】
Visitors related to Hiroshima International Council for Health Care of the Radiation Exposed(HICARE): 9 people
1) United States (3 people）
August 29, 2023: 3 trainees
2) South Korea (6 people）
Short-term training group of medical treatment for A-bomb survivors living in South Korea
December 5, 2023: 6 trainees【Nagasaki 24 people】
Visitors related to the Nagasaki Association for Hibakushas’ Medical Care (NASHIM):
24 people
1）Kazakhstan:
July 28, 2023: 5 trainees2）Korea(1) October 18, 2024: 6 trainees(2) January 24, 2024: 11 trainees3）Brazil
January 24, 2024: 2 trainees

11（Attachment 2）

FY2023
Joint programs between RERF and overseas researchers/research organizations
In italics: Funding Organization
1. Collaborative studies between RERF and US National Cancer Institute (NCI)(1) Under the research contract entered into by and between RERF and the US National
Cancer Institute (NCI), in which Kotaro Ozasa, Former Department Chief of
Epidemiology, served as a responsible person of the RERF side, analysis of solid cancer
incidence risks in the LSS cohort, site-specific cancer studies based on histopathologicaldiagnoses were conducted based on this contract.
The following papers have been published (RERF authors underlined):
Yoshida N, Fujihara M, Preston DL, Ozasa K, Hida A, Ohishi W, Sakata R, Mabuchi K.
Further analysis of incidence of multiple myeloma among atomic bomb survivors, 19501994. Blood Advances 2023 (June); 7(12):2807-10 [RP-3-94]
Utada M, Brenner AV, Preston DL, Yamada M, Grant EJ, Sugiyama H, Sakata R, Cahoon
EK, Ozasa K, Mabuchi K. The effect of prostate-specific antigen (PSA) test on radiation
risk estimate for prostate cancer incidence among atomic-bomb survivors. Radiat Res
2023 (July); 200(1):96-101[RP-S5-19]
Note: The contract research agreement between RERF and NCI, dated May 20, 2019,
expired on July 31, 2021.
(2) Ritsu Sakata, Acting Department Chief, and Alina Brenner, Senior Scientist, Departmentof Epidemiology, are joining with the data of tumor of the central nervous system fromRERF as a part of the pooled analysis conducted by the scientists of Radiation
Epidemiology Branch, NCI.
(3) Ritsu Sakata, Acting Department Chief of Epidemiology, is joining with the data ofradiation-associated thyroid cancers from RERF as a part of the pooled analysis conductedby the scientists of Radiation Epidemiology Branch, NCI.
2. Collaboration between RERF and the/Asia Cohort Consortium (ACC)
Ritsu Sakata, Acting Department Chief of Epidemiology, is joining the collaborative projectwith the ACC entitled: Tobacco smoking, alcohol drinking, body mass index and risk of rare
cancers.
3. Collaboration between RERF and Institute of Cancer Research, UK and US National Instituteof Environmental
Alina Brenner, Senior Scientist, Department of Epidemiology, is joining with premenopausal
breast cancer data from RERF as a part of the pooled analysis conducted by Dr. Anthony
Swerdlow of Institute of Cancer Research, UK, and Dr. Hazel Nichols of US National Instituteof Environmental.
4. Collaboration between RERF and The Federal Office for Radiation Protection,
Oberschleißheim, Germany.
Munechika Misumi is collaborating with Dr. Jan Christian Kaiser of the Federal Office for
Radiation Protection, Oberschleißheim, Germany, on the issue of mechanistic modelling of
the radiation risk for colon cancer in Japanese A-bomb survivors.
5. Collaboration between RERF and Columbia University, New York, USA
Zhenqiu Liu is collaborating with Drs. Sally Amundson, Igor Shuryak, and David Brenner, of
Columbia University, on the issue of candidate biomarker discovery, with focus on accurate

12radiation risk estimation using deep learning, double/debiased machine learning, and causal
gradient boosting.
6. Collaboration between RERF and Kyungpook National University, Korea
John Cologne is collaboration with Dr. Young Min Kim of Kyungpook National University,
Korea, on the issue of inference for the mediation proportion in causal models.
7. RERF international collaborative studies on radiation dosimetry.
Harry Cullings, Consultant, and Sachiyo Funamoto, Section Chief, Department of Statistics,
collaborated with an international group of dosimetry experts in work to update RERF
radiation dosimetry.
8. University of Bern international multi-institutional collaborative studies on thyroid
Misa Imaizumi, Assistant Department Chief of Clinical Studies (Nagasaki), Waka Ohishi,
Department Chief of Clinical studies and Michiko Yamada, Division Chief of Radiology of
Department of Clinical Studies are joining with Adult Health Study data from RERF as a partof the pooled analysis of thyroid conducted by Dr. Rodondi of University of Bern, Switzerland(Thyroid Studies Collaboration).
9. RERF international collaborative studies on cancer registries(1) Hiromi Sugiyama, Assistant Department Chief, Department of Epidemiology, submitted
data to the International Association of Cancer Registries (IACR)/International Agency
for Research on Cancer (IARC) Cancer Incidence on Five Continents using cancer
registry data from Hiroshima and Nagasaki, which was published in Volume 12.
(2) Hiromi Sugiyama, Assistant Department Chief, Department of Epidemiology, isparticipating in the CONCORD program at the London School of Tropical Hygiene andTropical Medicine, using data from the Hiroshima and Nagasaki cancer registries.
(3) Hiromi Sugiyama, Assistant Department Chief, Department of Epidemiology, isparticipating in the Rare Cancer Epidemiology Study in Asia (Rarecarenet Asia) using
data from the National Cancer Registry.

13令和5年度 外部資金研究一覧表
FY2023 External Research Funds

厚生労働省
Ministry of Health, Labour and Welfare (MHLW)

3

研究資金（資金拠出機関からの入金額）
Research funds(amount of funds from funding¥1,850,000

独立行政法人 日本学術振興会（文部科学省所管の独立行政法人）
Japan Society for the Promotion of Science (JSPS)9¥14,950,000

件数
Number of
Grants

外部機関名称
Name of Outside Organization[Independent administrative entity under the jurisdiction of the Ministry of Education, Culture,
Sports, Science and Technology (MEXT)]

一般財団法人 土谷記念医学振興基金
Tsuchiya Memorial Medical Foundation

1

¥0 *

国立研究開発法人 国立がんセンター
National Cancer Center

1

¥0 **

総合計

14

Grand total

注）・ 間接費を含む。
・ 研究分担者の配分額を含む。
* 研究期間延長のため、今年度資金の配分なし。
** 研究協力者として研究参画のため、資金の配分なし。
Notes)
・ These amounts include indirect cost.
・ These amounts include subsidies allocated to collaborators.
* No research funds are allocated in FY2023, because the research term has been extended.
** No research funds are allocated, because the RERF researcher takes part in the research as a cooperative investigator.

14¥16,800,000

令和5年度 外部資金研究一覧表
FY2023 External Research Funds

研究のタイトル
Title of Research

委託組織の名前と場所及び研究グループのチーフ又は担当の主任研究者
Name and location of entrusting outside organization
Chief of research group or principal investigator in charge

放影研における研究者の名前
Investigator(s) at RERF

研究資金（資金拠出機関からの入金額）
Research funds(amount of funds
from fundingorganizations)

令和5年度
令和5年度
開始日
終了日
関連RP
First project
Last project
Related RPs
date in FY2023 date in FY2023

関連性
Relationship to
RERF's mission

疫学部
Department of Epidemiology
1 社会経済的格差に着目したがん対策に資する空間
疫学的ビッグデータ解析研究
Spatial epidemiological big data analysis research that
contributes to cancer control focusing on socioeconomic disparities

日本学術振興会・科学研究費助成事業「基盤研究（B）」
研究代表者 伊藤 秀美
愛知県がんセンター
がん情報・対策研究分野 分野長
JSPS Grant-in-Aid for Scientific Research
Scientific Research (B)Hidemi Ito
Chief, Division of Cancer Information and Control, Aichi
Cancer Center Research Institute

研究分担者 (Collaborator)
杉山 裕美
Hiromi Sugiyama

直接経費(Direct cost)¥150,000

April 1, 2023

March 31, 2024

RP-S2-17

日本人のがんの疫学研究
Epidemiological study of cancer
in Japanese population

間接経費(Indirect cost)¥45,0002

がん統計を活用した、諸外国とのデータ比較に基づく日本のがん対策の評価のための研究
Research on the evaluation of cancer control in Japan
based on data comparison with oversea countries
using cancer statistics

厚生労働省・厚生労働科学研究費補助金「がん対策推進総合研究事業」
研究代表者 松田 智大
国立研究開発法人国立がん研究センター
がん対策研究所 国際政策研究部 部長
Health and Labour Sciences Research Grants (MHLW)
Promotion of Comprehensive Research Project for Cancer
Control
Tomohiro Matsuda
Chief, Division of International Health Policy Research,
National Cancer Center, Institute for Cancer Control

研究分担者 (Collaborator)
杉山 裕美
Hiromi Sugiyama¥650,000

April 1, 2023

March 31, 2024

RP-S2-17

日本人のがんの疫学研究
Epidemiological study of cancer
in Japanese population

3

診断・治療が特に困難ながんの実態把握と治療成績の向上に資する研究
Research that contributes to understanding the actual
status of cancers that are particularly difficult todiagnose and treat and to improving treatment
outcomes

厚生労働省・厚生労働科学研究費補助金「がん対策推進総合研究事業」
研究代表者 井上 真奈美
国立研究開発法人国立がん研究センター
がん対策研究所 予防研究部 部長
Health and Labour Sciences Research Grants (MHLW)
Promotion of Comprehensive Research Project for Cancer
Control
Manami Inoue
Chief, Division of Prevention,
National Cancer Center, Institute for Cancer Control

研究分担者 (Collaborator)
杉山 裕美
Hiromi Sugiyama¥400,000

November 8,
2023

March 31, 2024

RP-S2-17

日本人のがんの疫学研究
Epidemiological study of cancer
in Japanese population

15令和5年度 外部資金研究一覧表
FY2023 External Research Funds

研究のタイトル
Title of Research

委託組織の名前と場所及び研究グループのチーフ又は担当の主任研究者
Name and location of entrusting outside organization
Chief of research group or principal investigator in charge

放影研における研究者の名前
Investigator(s) at RERF

研究資金（資金拠出機関からの入金額）
Research funds(amount of funds
from fundingorganizations)

令和5年度
令和5年度
開始日
終了日
関連RP
First project
Last project
Related RPs
date in FY2023 date in FY2023

関連性
Relationship to
RERF's mission

疫学部
Department of Epidemiology
4

科学的根拠に基づくがんリスク評価とがん予防ガイ
ドライン提言に関する研究
Study for evaluation of cancer risk and proposal ofcancer prevention guidelines on the basis of scientificevidence

国立がん研究センター・国立がん研究センター研究
開発費
研究代表者 井上 真奈美
国立研究開発法人国立がん研究センター
がん対策研究所 予防研究部 部長
National Cancer Center
Funds for Cancer Research and Related Technology
Development
Manami Inoue
Chief, Division of Prevention,
National Cancer Center, Institute for Cancer Control

研究協力者(Cooperative Investigator)
歌田 真依
Mai Utada

16

研究協力者のため、研究資金の配分なし
Since this person is acooperative
investigator, researchfunds were notallocated to her.

April 1, 2023

March 31, 2024

RP-A2-15

日本人のがんの疫学研究
Epidemiological study of cancer
in Japanese population

令和5年度 外部資金研究一覧表
FY2023 External Research Funds

研究のタイトル
Title of Research

委託組織の名前と場所及び研究グループのチーフ又は担当の主任研究者
Name and location of entrusting outside organization
Chief of research group or principal investigator in charge

研究資金（資金拠出機関からの入金額）
Research funds(amount of funds
from fundingorganizations)

令和5年度
開始日
First projectdate in FY2023¥800,000

April 1, 2023

March 31, 2024

RP 2-75
RP 6-08
RP 1-15
RP-S1-23

広範囲な医学的調査（生活習慣病）
Broad-based medical research(Lifestyle disease)

研究代表者 (P.I.)
吉田 稚明
Noriaki Yoshida

直接経費(Direct cost)¥1,900,000

April 1, 2023

March 31, 2024

研究分担者 (Collaborator)
濱崎 幹也（分子生物科学部）
Kanya Hamasaki(Dept. Molecular Biosciences)

間接経費(Indirect cost)¥570,000

RP 6-70
RP 5-90
RP 3-94
RP-S2-15
RP 5-02
RP-P2-19

がん研究（被爆者がん研究への応用）
Cancer research(Application to cancer researchamong A-bomb survivors)

RP 6-70
RP 5-90
RP-S2-15
RP 5-02

がん研究（被爆者がん研究への応用）
Cancer research(Application to cancer researchamong A-bomb survivors)

放影研における研究者の名前
Investigator(s) at RERF

令和5年度
終了日
関連RP
Last project
Related RPs
date in FY2023

関連性
Relationship to
RERF's mission

臨床研究部
Department of Clinical Studies
12

循環器疾患及び糖尿病、COPD等の生活習慣病の個人リスク及び集団リスクの評価ツールの開発と応用のための研究
Research on the development and application ofindividual and population risk assessment tools forlifestyle-related diseases, including cardiovasculardisease, diabetes and COPD

造血器腫瘍における放射線被ばくに伴うゲノム異常と間質リモデリングの同定
Identification of radiation-related genomic alterations
and stromal remodeling in hematologicalmalignancies

厚生労働省・厚生労働科学研究費補助金「循環器疾患・糖尿病等生活習慣病対策総合研究事業」

研究代表者 村上 義孝
東邦大学医学部 教授
Health and Labour Sciences Research Grants (MHLW)
Comprehensive Research on Life-Style Related Diseases
including Cardiovascular Diseases and Diabetes Mellitus
Yoshitaka Murakami
Professor,
Graduate School of Medicine, Toho University

日本学術振興会・科学研究費助成事業「基盤研究（C）」
研究代表者 吉田 稚明
JSPS Grant-in-Aid for Scientific Research
Scientific Research (C)Noriaki Yoshida

研究分担者 (Collaborator)
立川 佳美
Yoshimi Tatsukawa
研究協力者(Cooperative Investigator)
山田 美智子Michiko Yamada

久留米大学の研究分担者への配分額は、上記の研究資金に含まれている。
The above amount includes funds allocated to thecollaborators at Kurume University.

3

被爆後早期に発症した白血病症例の分子病理学
的解析
Pathological and molecular characterization ofleukemia developed shortly after A-bomb radiation
exposure

一般財団法人 土谷記念医学振興基金研究代表者 吉田 稚明
Tsuchiya Memorial Medical Foundation
Noriaki Yoshida

研究代表者 (P.I.)
吉田 稚明
Noriaki Yoshida¥0

April 1, 2023

March 31, 2024

研究期間延長により、令和4年度の未執行額（846,431円）を使用。令和5年度に新たな助成金の交付はなし。
With extension of the research term, the unexecutedamount for FY2022 (846,431yen) has been used. No grant
was provided for FY2023.

17令和5年度 外部資金研究一覧表
FY2023 External Research Funds

研究のタイトル
Title of Research

委託組織の名前と場所及び研究グループのチーフ又は担当の主任研究者
Name and location of entrusting outside organization
Chief of research group or principal investigator in charge

放影研における研究者の名前
Investigator(s) at RERF

研究資金（資金拠出機関からの入金額）
Research funds(amount of funds
from fundingorganizations)

令和5年度
開始日
First projectdate in FY2023

令和5年度
終了日
関連RP
Last project
Related RPs
date in FY2023

関連性
Relationship to
RERF's mission

統計部
Department of Statistics
1 Fused-lassoによる広島・長崎の被爆に関する時空間リスク推定モデルの開発
Development of a spatio-temporal risk estimation modelfor Hiroshima and Nagasaki exposures by Fused-lasso

日本学術振興会・科学研究費助成事業「基盤研究（B）」
研究代表者 山村 麻理子
JSPS Grant-in-Aid for Scientific Research
Scientific Research (B)Mariko Yamamura

研究代表者 (P.I.)
山村 麻理子Mariko Yamamura

直接経費(Direct cost)¥2,400,000

April 1, 2023

March 31, 2024

RP 1-75

LSS

RP-S4-18
RP18-61

LSS
LSS

間接経費
(Indirect cost)¥720,000
広島大学、東北大学及び関西大学の研究分担者への配分額は、上記の研究資金に含まれている。
The above amount includes funds allocated to thecollaborators at Hiroshima University, Tohoku University
and Kansai Uinversity.

2 疫学データに基づく大腸がんの放射線発がん機序
モデリングとその妥当性の検討
Biology-based mechanistic modelling of colorectal
cancer based on epidemiological data and investigationsof its validity

日本学術振興会・科学研究費助成事業「基盤研究（C） 」
研究代表者 三角 宗近
JSPS Grant-in-Aid for Scientific Research
Scientific Research (C)Munechika Misumi

研究代表者 (P.I.)
三角 宗近
Munechika Misumi

直接経費(Direct cost)¥1,000,000
間接経費(Indirect cost)¥300,00018

April 1, 2023

March 31, 2024

令和5年度 外部資金研究一覧表
FY2023 External Research Funds

研究のタイトル
Title of Research

委託組織の名前と場所及び研究グループのチーフ又は担当の主任研究者
Name and location of entrusting outside organization
Chief of research group or principal investigator in charge

放影研における研究者の名前
Investigator(s) at RERF

研究資金（資金拠出機関からの入金額）
Research funds(amount of funds
from fundingorganizations)

令和5年度
開始日
First projectdate in FY2023

令和5年度
終了日
関連RP
Last project
Related RPs
date in FY2023

関連性
Relationship to
RERF's mission

分子生物科学部
Department of Molecular Biosciences
1 原爆被爆者のクローン造血と体細胞変異に基づく時間
分解バイオドシメトリ
Time-resolved biodosimetry based on clonal
hematopoiesis and somatic mutations in atomic-bomb
survivors

日本学術振興会・科学研究費助成事業「基盤研究（B）」
研究代表者 吉田 健吾
JSPS Grant-in-Aid for Scientific Research
Scientific Research (B)Kengo Yoshida

研究代表者 (P.I.)
吉田 健吾
Kengo Yoshida

直接経費(Direct cost)¥4,000,000

研究分担者 (Collaborator)
楠 洋一郎
Yoichiro Kusunoki
内村 有邦
Arikuni Uchimura
田邉 修
Osamu Tanabe
濱崎 幹也
Kanya Hamasaki

間接経費(Indirect cost)¥1,200,000

April 1, 2023

March 31, 2024

RP1-23-1

被ばくに関連した変異クローンの生成時期の推定を目指し、新規バイオドシメトリ法の開発に貢献
This study contributes to thedevelopment of a novel
biodosimetry method aimed at
estimating the timing of generationof mutant clones associated with
exposure.

April 1, 2023

March 31, 2024

No.RP

放射線被ばくにおける肝疾患発症のメカニズム研究
Mechanistic analysis of radiationassociated development of liverdiseases

研究協力者(Cooperative Investigator)
John B. Cologne（統計部）(Dept. Statistics)

2ブタモデルを用いたFOLFOX誘導性のSOSの予防法の確立
Establishment of a preventive method of FOLFOXinduced SOS using a porcine model

日本学術振興会・科学研究費助成事業「基盤研究（C）」
研究代表者 瀬尾 智
高知大学 医学部 教授
JSPS Grant-in-Aid for Scientific Research
Scientific Research (C)Satoru Seo
Professor, School of Medicine, Kochi University

研究分担者 (Collaborator)
鶴山 竜昭Tatsuaki Turuyama

直接経費(Direct cost)¥50,000
間接経費(Indirect cost)¥15,00019

令和5年度 外部資金研究一覧表
FY2023 External Research Funds

研究のタイトル
Title of Research

委託組織の名前と場所及び研究グループのチーフ又は担当の主任研究者
Name and location of entrusting outside organization
Chief of research group or principal investigator in charge

放影研における研究者の名前
Investigator(s) at RERF

研究資金（資金拠出機関からの入金額）
Research funds(amount of funds
from fundingorganizations)

令和5年度
開始日
First projectdate in FY2023

令和5年度
終了日
関連RP
Last project
Related RPs
date in FY2023

関連性
Relationship to
RERF's mission

分子生物科学部
Department of Molecular Biosciences3

デング熱感染回復期の細胞障害性T細胞抗原受容体レパトアのシングルセル解析
Single cell analysis of TCR genotypes of CTL atrecovery phase of acute Dengue infection

日本学術振興会・科学研究費助成事業
研究分担者 (Collaborator)「基盤研究（B）」
谷本 幸介
研究代表者 平山 謙二
Kousuke Tanimoto
長崎大学 熱帯医学・グローバルヘルス研究科 教授
JSPS Grant-in-Aid for Scientific Research
Scientific Research (B)Kenji Hirayama
Professor, School of Tropical Medicine and Global Health,
Nagasaki University

20

直接経費
(Direct cost)¥0

April 1, 2023

March 31, 2024

間接経費
(Indirect cost)¥0
長崎大学の研究員（非常勤）の立場で研究分担者として当研究所の就業時間外に行われる。当該科研費の管理および係る交付申請、実績報告書等の提出事務はすべて長崎大学が行う。
As the part-time researcher of Nagasaki University, thisproject is performed outside working hours. All
management of this funds and submission of reprots,
etc. are done by Nagasaki University.

No.RP

該当なし
None

令和5年度 外部資金研究一覧表
FY2023 External Research Funds

研究のタイトル
Title of Research

委託組織の名前と場所及び研究グループのチーフ又は担当の主任研究者
Name and location of entrusting outside organization
Chief of research group or principal investigator in charge

放影研における研究者の名前
Investigator(s) at RERF

研究資金（資金拠出機関からの入金額）
Research funds(amount of funds
from fundingorganizations)

令和5年度
令和5年度
開始日
終了日
関連RP
First project
Last project
Related RPs
date in FY2023 date in FY2023

関連性
Relationship to
RERF's mission

情報技術部
Department of Information Technology
1 ワイヤレスセンシングと機械学習による猟師向けリアル

タイム獣流推定に関する研究
Study concerning the use of wireless sensing andmachine learning by hunters to estimate the movementsof wildlife real-time

日本学術振興会・科学研究費助成事業「若手研究 」
研究代表者 小野 悟
JSPS Grant-in-Aid for Scientific Research
Early-Career Scientists
Satoru Ono

研究代表者 (P.I.)
小野 悟
Satoru Ono

直接経費(Direct cost)¥600,000
間接経費(Indirect cost)¥180,00021

April 1, 2023

March 31, 2024

No RP

診療録を始めとする紙媒体のス
キャンデータを分類するための手法の構築には、本研究で用いる機械学習を用いた行動情報の分類に関する研究が有用に機能すると考えられる。
This research which will
examine machine-learning-based
dog's movement dataclassification, will expect tocontribute to the creation of abest-fit classification method for
medical charts and other paper
documents.

令和5年度 外部資金研究一覧表
FY2023 External Research Funds

研究のタイトル
Title of Research

委託組織の名前と場所及び研究グループのチーフ又は担当の主任研究者
Name and location of entrusting outside organization
Chief of research group or principal investigator in charge

放影研における研究者の名前
Investigator(s) at RERF

研究資金（資金拠出機関からの入金額）
Research funds(amount of funds
from fundingorganizations)

令和5年度
開始日
First projectdate in FY2023

令和5年度
終了日
関連RP
Last project
Related RPs
date in FY2023

関連性
Relationship to
RERF's mission

バイオサンプル研究センター
Biosample Research Center1 ヒト造血幹細胞における放射線誘発変異の全ゲノムシーケンスによる解析
Whole-genome sequence analysis of radiation-induced
somatic mutations in human hematopoietic stem cells

日本学術振興会・科学研究費助成事業「基盤研究（C） 」
研究代表者 田邉 修
JSPS Grant-in-Aid for Scientific Research
Scientific Research (C)Osamu Tanabe

研究代表者 (P.I.)
田邉 修
Osamu Tanabe

直接経費(Direct cost)¥1,400,000

研究分担者 (Collaborator)
松田 由喜子（分子生物科学部）
Yukiko Matsuda(Dept. Molecular Biosciences)
吉田 健吾（分子生物科学部）
Kengo Yoshida(Dept. Molecular Biosciences)
内村 有邦（分子生物科学部）
Arikuni Uchimura(Dept. Molecular Biosciences)

間接経費(Indirect cost)¥420,00022

April 1, 2023

March 31, 2024

No RP

放射線被曝による晩発障害である白血病、固形腫瘍、循環器疾患などの分子メカニズムの解明と、それら疾患の予防法、治療法の開発に貢献
This study contributes to theelucidation of molecularmechanisms of the late-onset
diseases by radiation exposure,including leukemia, solid tumors,and cardiovascular diseases, andcontributes to the development ofpreventive and therapeuticmeasures for those diseases.

令和5年度 特別会計一覧表
FY2023 Special Funds
件数
Number ofFunds

資金拠出機関名称
Name of Funding Agency

資金合計
Amount of Funding
Total

厚生労働省
Ministry of Health, Labour and Welfare (MHLW)

2¥8,461,000

広島県
Hiroshima Prefecture1¥12,243,141

長崎県
Nagasaki Prefecture

1¥8,700,000

総合計

4¥29,404,141

Grand total

注）・ 間接費を含む。
・ 研究分担者の配分額を含む。
Notes)
・ These amounts include indirect cost.
・ These amounts may include subsidies allocated to collaborators.

23令和5年度 特別会計一覧表
FY2023 Special Funds
研究のタイトル
Title of Research

厚生労働省・労災疾病臨床研究事業費補助金
研究代表者 大久保 利晃
独立行政法人労働者健康安全機構 労働安
全衛生総合研究所 労働者放射線障害防止
研究センター センター長

放影研における契約者/
研究者の名前Investigator(s) at RERF

資金拠出機関からの入金額
Amount of Funds
from Funding
Agencies

開始日
Initiation
Date

終了日
Termination
Date

関連RP
Related RPs

関連性
Relationship to
RERF's mission

研究分担者(Collaborative Investigator)
大石 和佳
Waka Ohishi¥6,587,000

April 1,2023

March 31,2024

厚生労働省・委託事業
神谷 研二
MHLW Entrustment
Kenji Kamiya

受託者(Contractor)
神谷 研二
Kenji Kamiya¥1,874,000

January 25,
2024

March 31,2024

がん登録推進事業
Cancer Registry Promotional Project

広島県・委託事業
神谷 研二
Hiroshima Prefecture
Kenji Kamiya

受託者(Contractor)
神谷 研二
Kenji Kamiya¥12,243,141

April 1,2023

March 31,2024

RP18-61
RP29-60
RPs18-61&
29-60附属書

がんの疫学研究、
LSS、胎内被爆者、
F1集団
Epidemiological study of cancer,
LSS, in utero, andF1 populations

長崎県がん登録・評価事業
Nagasaki Prefecture Cancer Registry Program

長崎県・委託事業
神谷 研二
Nagasaki Prefecture
Kenji Kamiya

受託者(Contractor)
神谷 研二
Kenji Kamiya¥8,700,000

April 1,2023

March 31,2024

RP18-61
RP29-60
RPs18-61&
29-60附属書

がんの疫学研究、
LSS、胎内被爆者、
F1集団
Epidemiological study of cancer,
LSS, in utero, andF1 populations

放射線業務従事者の健康影響に関する疫学
研究
Epidemiological study of health effects inradiation workers

RP 6-15

Research Grant for Clinical Studies of WorkRelatedIllness (MHLW)
Toshiteru Okubo
Director, Research Center for Prevention from
Radiation Hazards of Workers, National Institute ofOccupational Safety and Health, Japan
Organization of Occupational Health and Safety

1

原爆被爆者の生物試料の保管及び活用に関する研究事業2 Research Program on preservation and use of
the A-bomb survivors' biosamples

3

4

委託組織の名前と場所及び研究グループのチーフ又は担当の主任研究者
Name and location of entrusting outsideorganization/Chief of research group or principal
investigator in charge24

東電福島第一原発事故処理緊急作業従事者の長期疫学調査
Long term follow-up
epidemiological study on
emergency workers of TEPCO,
Fukushima Daiichi Nuclear
Power Plant accident.

原爆被爆者の生物試料の保管
及び活用
Preservation and use of the Abomb survivors' biosamples

II. Operation and management of RERF
1. Research Resource Center
In order to accomplish the "Strategic Plan" of RERF, it is planned that the Research Resource
Center (RRC) will be established with the aims to modernize the research infrastructure of
RERF and to facilitate collaborative studies by streamlining research management system.
More specifically, the mission of the RRC is 3-fold as follows:(1) Preserve RERF's research assets and historical materials, which include various
paper materials for research, photographs, films, paper manuscripts, and datasets.
(2) Integrate all research data and biosample inventories to enhance the availability of
those research resources, and for this aim, provide tools and systems for datavisualization and data assembly.
(3) Create an Office of Research Support to provide an efficient administrative
framework to advance collaborative projects inside and outside RERF and facilitate
applications for contracts and grants.
As the endeavor of the Research Resource Section to preserve RERF's research assets andhistorical materials according to the mission (1) above, microfilms kept by the Departmentof Clinical Studies in Nagasaki were digitized. The degraded old microfilms needed to be
dealt with urgently. This work completed the digitization of all microfilms stored in RERF.
In addition, specifications were prepared to outsource digitization of the negative films ofchromosome images and their ledgers held by the Department of Molecular Biosciences.
Furthermore, a policy was developed for prioritizing the digitization and integration ofresearch resources stored in each department at RERF. The prioritization was to be decided
by the RERF Board of Directors after discussion at the Research Resource Center Operating
Committee (RRCOC), based on RERF's "Strategic Plan" with reference to research
scenarios developed by each department, and taking into consideration the future use
probability and frequency of the research resources, as well as the budget and time frame
required for digitization. Regarding (2), a plan was approved to link the research databasecurrently in operation with the biosample database created by the Laboratory Information
Management System (LIMS) that manages biosamples, and with the consent information
database being created by the Departments of Clinical Studies, to construct an integrated
research data source. In addition, it was decided to share information within RERF using
Tableau® software, which extracts data from electronic information within the Foundationand visualizes it for at-a-glance viewing. Since Tableau Server® software for sharing digital
dashboards has already been implemented in RERF, we plan to use this environment to sharethe visualized information. For the establishment of the Office of Research Support as
described in (3), the Departments of Epidemiology and Information Technology are working
together to select practical staff.
2. Relocation of the Hiroshima Laboratory
RERF concluded an entrustment contract for design and supervision with Naito Architects
Co., Ltd., as of June 7, 2023, and the process of detailed design for the new building was
initiated. The design process was originally scheduled to be completed by the end of January2024 but was extended due to changes in design and rising construction-material prices.

25

3. Full audit
The audit report on the voluntary audit (full audit), which is a new process taken fromFY2022, was submitted to the Auditors by the auditing firm on May 31, 2023. At the annual
BOC meeting in FY2023, the Directors reported on the progress made in establishing audit
system, and the Auditors presented their audit report.
An audit contract for FY2023 was signed with Deloitte Touche Tohmatsu LLC on
November 1, 2023, and a voluntary audit was initiated. The audit has been being conductedsince the contract date and will continue through June 30, 2024.
The specifics of the audit performed, as of the end of March 2024, are as follows:First-round audit at RERF, December 19, 21, 25–26, 2023
Assessment of preparation and implementation of internal control: Processes for
subsidy revenues, purchase, fixed assets management, inventory management,salaries, and financial management.
 Second-round, Briefing on audit plans and discussion with management, January 12,2024
1. Briefing on audit plans
2. Discussion with the Chair: Environmental analysis, major managerial issues,
understanding of general situation of RERF in the current fiscal year.
 Third-round audit, March 29, 2024
Substantive procedures taken during the fiscal year: witnessing for stocktaking,physical inspection of cash, confirmation of bank balances, confirmation with alawyer.

Upon completion of the audit, the final report will be submitted to the Auditors by theregular meeting of the Board of Directors in June 2024.
4. Revision of the rules and regulations
RERF in FY2023 continued to review its regulations to enhance the foundation’s operationalframework as a public interest incorporated foundation. The following are main regulations
revised or established.
Supplementary Regulations Concerning Organization of the Laboratory (Research
Departments) [Effected on April 1, 2023]
The supplementary regulations were updated to reflect the establishment of the Research
Resource Section in the Information Technology Department as part of the Research
Resource Center (RRC) plan.

Regulatory amendments due to the increase in mandatory retirement age [Effected on April
1, 2023]
Due to the foundation’s adoption of the national government’s system to raise theretirement age in steps, the Rules of Employment, Wage-related Regulations, and otherrelevant standards were revised.

Supplementary Regulations Concerning Handling of Specific Assets [Effected on April 1,
2023 (applicability date: April 1, 2022)]26

Due to the Accounting Standards for Nonprofit Organizations’ requirement that those notdeemed basic assets be recorded as specific assets, the supplementary regulations on such
assets’ handling were established.
Regulations on Prevention of Harassment and Others [Effected on April 1, 2023]
As it was made obligatory for employers to take measures required for personnel
management to prevent power harassment at workplace, RERF also established its
regulations to enhance the foundation’s measures to prevent the harassment.

Procedures for Characterizing Autopsy Samples and Database management [Applied fromMay 30, 2023]
Written procedures for characterizing autopsy samples were established to facilitate
molecular pathology research in the future.

Regulations on Management Authority of Directors [Applied from August 4, 2023]
With the new Directors’ arrival at RERF, their duties were re-evaluated to revise theappended table related to Article 7: Duties of Directors.

 Payment of Expenses for Activities of Outside Experts, Including Consultants and Visiting
Research Associates [Applied from October 1, 2023]
The amount of honorarium for industrial physicians and consultants were revised.

27

Appended documents to FY2023 report of activities

There were no items considered to be important matters for supplementing thecontents of the FY2023 report of activities.

28